0656 Severe Air Pollution as a Possible Triggering Factor for Kleine-levin Syndrome

Arezou Heshmati
DOI: https://doi.org/10.1093/sleep/zsae067.0656
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Kleine-Levin Syndrome (KLS) is a rare neurological disorder characterized by recurrent episodes of hypersomnia, altered behavior, and cognitive disturbances. We report a case where severe air pollution seemingly acted as a trigger for a KLS episode in a patient with a history of viral-triggered and alcohol-associated episodes. Methods We present a case of a 17-year-old girl with a history of anxiety and migraine headaches, effectively managed with a stable dose of Lexapro 20 mg per day. The patient experienced multiple episodes of Kleine-Levin Syndrome (KLS) following viral infections and alcohol consumption. However, the fourth episode was distinct, as it coincided with extreme air pollution in New York City. On the day that her symptoms started the Air Quality Index was reported to be above 480 technically off the chart. While there were no other known triggers for this fourth episode and the duration of the fourth episode was similar to the previous three ones. Results This case sheds light on potential environmental triggers for KLS and highlights the importance of understanding individual susceptibilities within this rare disorder. Conclusion This case emphasizes the need for a comprehensive approach to understanding KLS triggers, including environmental factors. The possibility of severe air pollution acting as a trigger adds a new dimension to our understanding of this enigmatic disorder. Further research is required to elucidate the relationship between air pollution and KLS, potentially offering insights into preventive strategies and tailored interventions for susceptible individuals. Support (if any)
neurosciences,clinical neurology
What problem does this paper attempt to address?
### What problems does this paper attempt to solve? This paper mainly explores **the natural course of idiopathic hypersomnia (IH) and its symptom changes**. Specifically, the study aims to answer the following key questions: 1. **How do the symptoms of IH patients change over time?** - The study evaluated the symptom changes of IH patients over many years by analyzing longitudinal data in a large - scale registration database. In particular, the study focused on changes in excessive daytime sleepiness, prolonged sleep time, difficulty in awakening, cognitive symptoms, etc. 2. **What is the treatment effect of IH?** - The study also evaluated the changes in IH patients before and after receiving drug treatment, especially the use of commonly used drugs such as modafinil, amphetamine - dextroamphetamine, methylphenidate and armodafinil and their effects on symptoms. 3. **Can current treatments effectively control the symptoms of IH?** - The study results show that although some symptoms have improved or worsened, overall, the symptoms of IH remain relatively stable within 2.5 years. This suggests the limitations of current treatment regimens in comprehensively controlling symptoms. ### Main findings - **Symptom stability**: Most symptoms (such as excessive daily sleepiness, long sleep time, intentional or unintentional naps, the need for multiple alarm clocks, brain fog, etc.) did not change significantly within two and a half years. - **Symptom improvement and worsening**: - The symptom of difficulty in awakening improved slightly (decreased from 78.7% to 73.0%, p = 0.01). - The symptom of automatic behavior worsened slightly (increased from 9.9% to 12.8%, p = 0.05). - **Drug use changes**: The usage rate of modafinil decreased significantly (from 33.0% to 25.1%, p = 0.0005), while the usage rates of other commonly used drugs remained basically unchanged. - **Limited treatment effect**: Although 79.5% of patients had been receiving treatment during this period, a high proportion of patients still reported persistent symptoms, indicating that current treatments have failed to achieve comprehensive symptom control. ### Conclusion The study results show that the symptoms of IH remain basically stable within 2.5 years, which may mean that the disease will not progress significantly over time. However, the high proportion of residual symptoms also indicates that current treatment methods are insufficient in comprehensively controlling symptoms. Future research needs to explore more effective treatment strategies to improve the quality of life of IH patients. ### Supporting information This study was supported by NS111280, with the citation ID of zsae067.0655.